Abstract
This quality improvement study characterizes surgical oncology trials, analyzes growth, identifies associations with early discontinuation or results reporting, and evaluates proportions of trials involving each neoplasm site.
Highlights
Surgical interventions are essential in the treatment of solid organ tumors, yet surgical interventions are infrequently studied via clinical trials.[1,2] This study characterizes surgical oncology trials registered on ClinicalTrials.gov, analyzes growth, identifies associations with early discontinuation or results reporting, and evaluates proportions of trials involving each neoplasm site.Author affiliations and article information are listed at the end of this article
Primary outcomes were early discontinuation and results reporting in the ClinicalTrials.gov database
Surgical oncology trials increased at a rate of 9.5% from 2008 to 2020
Summary
Surgical interventions are essential in the treatment of solid organ tumors, yet surgical interventions are infrequently studied via clinical trials.[1,2] This study characterizes surgical oncology trials registered on ClinicalTrials.gov, analyzes growth, identifies associations with early discontinuation or results reporting, and evaluates proportions of trials involving each neoplasm site.Author affiliations and article information are listed at the end of this article.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
